US 12,077,793 B2
Immunotherapeutic potential of modified lipooligosaccharides/lipid A
Robert K. Ernst, Silver Spring, MD (US); Mark Pelletier, Brunswick, MD (US); and Adeline Hajjar, Seattle, WA (US)
Assigned to University of Maryland, Baltimore, Baltimore, MD (US); and University of Washington, Seattle, WA (US)
Filed by University of Maryland, Baltimore, Baltimore, MD (US); and UNIVERSITY OF WASHINGTON, Seattle, WA (US)
Filed on Aug. 23, 2021, as Appl. No. 17/445,708.
Application 16/431,536 is a division of application No. 14/772,282, granted, now 10,358,667, issued on Jul. 23, 2019, previously published as PCT/US2014/022121, filed on Mar. 7, 2014.
Application 17/445,708 is a continuation of application No. 16/431,536, filed on Jun. 4, 2019, granted, now 11,124,815.
Claims priority of provisional application 61/773,928, filed on Mar. 7, 2013.
Prior Publication US 2021/0381015 A1, Dec. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 11/04 (2006.01); A61K 31/739 (2006.01); A61K 39/02 (2006.01); A61K 39/39 (2006.01); C12P 19/12 (2006.01); C12P 19/26 (2006.01); C12P 19/44 (2006.01); A61K 39/00 (2006.01)
CPC C12P 19/12 (2013.01) [A61K 31/739 (2013.01); A61K 39/0291 (2013.01); A61K 39/099 (2013.01); A61K 39/39 (2013.01); C07H 11/04 (2013.01); C12P 19/26 (2013.01); C12P 19/44 (2013.01); A61K 2039/55572 (2013.01)] 3 Claims
 
1. A biosynthetic lipid polysaccharide compound of formula (I) or formula (II)

OG Complex Work Unit Chemistry
or a salt thereof.